FLEMINGTON, N.J.--(BUSINESS WIRE)--NovaDel Pharma Inc. (NYSE AMEX: NVD), today announced that it received an Issue Notification from the United States Patent and Trademark Office (USPTO) for a new U.S. Patent, No. 7632517, entitled “Buccal, Polar and Non-polar Spray Containing Zolpidem,” which covers a method of treating insomnia by administering zolpidem to humans utilizing NovaDel’s oral spray technology.
